Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Injection site erythema Reports for Measles, Mumps & Rubella (MMR II)
#3 most reported symptom for this vaccine
Injection site erythema and Measles, Mumps & Rubella (MMR II)
Injection site erythema has been reported 11,502 times in association with Measles, Mumps & Rubella (MMR II) vaccination in VAERS. This represents 12.8% of all 89,976 reports for this vaccine.
Among these reports, 0 mentioned death (0.00%) and 132 involved hospitalization (1.1%).
Injection site erythema is the #3 most frequently reported symptom for Measles, Mumps & Rubella (MMR II) out of 2292 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
What This Means
Seeing 11,502 reports of Injection site erythema after Measles, Mumps & Rubella (MMR II) vaccination may seem alarming, but context is critical.
The mortality rate among these reports is very low at 0.00%, suggesting most cases are non-fatal.
Important Context
Similarly Ranked Symptoms
Quick Facts
Related Pages
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.